Robert Williams's most recent trade in Donnelley Financial Solutions Inc was a trade of 16,450 Common Stock done at an average price of $48.8 . Disclosure was reported to the exchange on Sept. 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Intl Officer | Sale of securities on an exchange or to another person at price $ 48.77 per share. | 03 Sep 2026 | 16,450 | 44,353 (0%) | 0% | 48.8 | 802,191 | Common Stock |
| Tenaya Therapeutics Inc | Robert Sanders Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2026 | 120,000 | 120,000 | - | - | Stock Option (Right to buy) | |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2026 | 13,256 | 69,441 (0%) | 0% | - | Common Stock | |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Grant, award, or other acquisition of securities at price $ 51.77 per share. | 03 Mar 2026 | 10,292 | 62,518 (0%) | 0% | 51.8 | 532,817 | Common Stock |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Sale of securities on an exchange or to another person at price $ 52.03 per share. | 03 Mar 2026 | 7,684 | 60,803 (0%) | 0% | 52.0 | 399,786 | Common Stock |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.77 per share. | 03 Mar 2026 | 7,533 | 54,985 (0%) | 0% | 51.8 | 389,983 | Common Stock |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Sale of securities on an exchange or to another person at price $ 52.29 per share. | 03 Mar 2026 | 4,237 | 54,578 (0%) | 0% | 52.3 | 221,556 | Common Stock |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.77 per share. | 03 Mar 2026 | 2,352 | 52,226 (0%) | 0% | 51.8 | 121,763 | Common Stock |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2026 | 1,200 | 56,185 (0%) | 0% | - | Common Stock | |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.97 per share. | 03 Mar 2026 | 954 | 68,487 (0%) | 0% | 53.0 | 50,533 | Common Stock |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Sale of securities on an exchange or to another person at price $ 56.54 per share. | 10 Jun 2025 | 10,000 | 58,815 (0%) | 0% | 56.5 | 565,376 | Common Stock |
| Tenaya Therapeutics Inc | Robert Sanders Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 107,400 | 107,400 | - | - | Stock Option (Right to buy) | |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Sale of securities on an exchange or to another person at price $ 52.09 per share. | 07 May 2025 | 4,703 | 68,815 (0%) | 0% | 52.1 | 244,979 | Common Stock |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Grant, award, or other acquisition of securities at price $ 47.54 per share. | 03 Mar 2025 | 9,960 | 66,979 (0%) | 0% | 47.5 | 473,498 | Common Stock |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 9,742 | 74,472 (0%) | 0% | - | Common Stock | |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.54 per share. | 03 Mar 2025 | 6,784 | 60,195 (0%) | 0% | 47.5 | 322,511 | Common Stock |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 4,535 | 64,730 (0%) | 0% | - | Common Stock | |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.54 per share. | 03 Mar 2025 | 1,964 | 57,019 (0%) | 0% | 47.5 | 93,369 | Common Stock |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.10 per share. | 03 Mar 2025 | 954 | 73,518 (0%) | 0% | 46.1 | 43,979 | Common Stock |
| Tenaya Therapeutics Inc | Robert Sanders Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2024 | 34,000 | 34,000 | - | - | Stock Option (Right to buy) | |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Sale of securities on an exchange or to another person at price $ 63.57 per share. | 03 May 2024 | 18,229 | 58,983 (0%) | 0% | 63.6 | 1,158,814 | Common Stock |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Sale of securities on an exchange or to another person at price $ 63.83 per share. | 03 May 2024 | 855 | 77,212 (0%) | 0% | 63.8 | 54,577 | Common Stock |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Grant, award, or other acquisition of securities at price $ 65.53 per share. | 04 Mar 2024 | 11,308 | 72,461 (0%) | 0% | 65.5 | 741,013 | Common Stock |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.53 per share. | 04 Mar 2024 | 9,419 | 63,042 (0%) | 0% | 65.5 | 617,227 | Common Stock |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 7,757 | 70,799 (0%) | 0% | - | Common Stock | |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 7,268 | 78,067 (0%) | 0% | - | Common Stock | |
| Donnelley Fin Soln Inc | Robert Kirk Williams | Chief People & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 64.58 per share. | 03 Mar 2024 | 3,077 | 61,153 (0%) | 0% | 64.6 | 198,713 | Common Stock |
| Labcorp | Williams Sanders Robert | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 947 | 8,120 (0%) | 0% | - | Common Stock | |
| Labcorp | Williams Sanders Robert | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 947 | 236 | - | - | Restricted Stock Unit | |
| Labcorp | Williams Robert Sanders | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 236 | 1,183 | - | - | Restricted Stock Unit | |
| Tenaya Therapeutics Inc | Robert Sanders Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 29,532 | 29,532 | - | - | Stock Option (Right to buy) | |
| Amgen | Robert Sanders Williams | Director | 19 May 2023 | 939 | 6,240 (0%) | 0% | 0 | Common Stock | ||
| Labcorp | Robert Sanders Williams | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 742 | 7,173 (0%) | 0% | - | Common Stock | |
| Labcorp | Robert Sanders Williams | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 742 | 849 | - | - | Restricted Stock Unit | |
| Labcorp | Robert Sanders Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 849 | 1,591 | - | - | Restricted Stock Unit | |
| Amgen | Robert Sanders Williams | Director | 22 Aug 2022 | 200 | 5,301 (0%) | 0% | 250.0 | 49,992 | Common Stock | |
| Angel Oak Mortgage REIT Inc | Robert Williams | CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 24,359 | 221,726 | - | 0 | Common Stock | |
| Tenaya Therapeutics Inc | Robert Sanders Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 39,727 | 39,727 | - | - | Stock Option (Right to buy) | |
| Amgen | Robert Sanders Williams | Director | 23 May 2022 | 600 | 5,501 (0%) | 0% | 250 | 150,000 | Common Stock | |
| Amgen | Robert Sanders Williams | Director | 17 May 2022 | 855 | 6,101 (0%) | 0% | 0 | Common Stock | ||
| Labcorp | Robert Sanders Williams | Director | Sale of securities on an exchange or to another person at price $ 272.98 per share. | 25 Mar 2022 | 572 | 6,431 (0%) | 0% | 273.0 | 156,145 | Common Stock |
| Labcorp | Robert Sanders Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 742 | 742 | - | - | Restricted Stock Unit | |
| Labcorp | Robert Sanders Williams | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2022 | 771 | 7,003 (0%) | 0% | - | Common Stock | |
| Labcorp | Robert Sanders Williams | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2022 | 771 | 0 | - | - | Restricted Stock Unit |